Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

MLA

Biagio Ricciuti, Md, PhD, et al. “Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.” JTO Clinical and Research Reports, vol. 5, no. 9, Sept. 2024. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2024.100675.

APA

Biagio Ricciuti, M., PhD, Arielle Elkrief, M., Jessica Lin, M., Jianjun Zhang, M., Joao V. Alessi, M., Giuseppe Lamberti, M., PhD, Malini Gandhi, M., Alessandro Di Federico, M., Federica Pecci, M., Xinan Wang, P., Maisam Makarem, M., PhD, Cassio Murilo Hidalgo Filho, M., Teresa Gorria, M., Arushi Saini, B., Cindy Pabon, M., James Lindsay, P., Kathleen L. Pfaff, P., Emma L. Welsh, B., Mizuki Nishino, M., … Mark M. Awad, M., PhD. (2024). Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab. JTO Clinical and Research Reports, 5(9). https://doi.org/10.1016/j.jtocrr.2024.100675

Chicago

Biagio Ricciuti, Md, PhD, Md Arielle Elkrief, Md Jessica Lin, Md Jianjun Zhang, Md Joao V. Alessi, Md Giuseppe Lamberti PhD, Md Malini Gandhi, et al. 2024. “Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.” JTO Clinical and Research Reports 5 (9). doi:10.1016/j.jtocrr.2024.100675.